Groundbreaking Strides in B-Cell Lymphoma Treatment

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, gives an overview of the exciting therapeutic developments in the B-cell lymphoma space. 


I guess one of the things that I found really fascinating about the pathway is what’s going on in B-cell lymphoma. There’s some work being done and it goes back to the Cancer Moonshot campaign and you know, with the 21st Century Cares Act then Congress earmarked $1.8 billion for a Cancer Moonshot. So different institutions are taking part in this. We have MD Anderson and Dr. Michael Wang is leading the way. And we saw an approval in acalabrutinib and this is a selective Bruton’s tyrosine kinase inhibitor. It should have less side effects than what we see on the market today, but just phenomenal as far as overall survival for these patients. So I think this is the first, what we see with the goal of the moonshot, particularly in B cell lymphoma where right now we have an overall 30% response rate to increase to 60 and plus percent and increasing in overall survival.

Related Articles

A phase 2a study is evaluating cerdulatinib, an oral SYK/JAK inhibitor, in pre-treated patients with relapsed/refractory follicular lymphoma.
The supplemental New Drug Application supports the expansion of niraparib’s indication as a late-line therapeutic option for patients with ovarian cancer.
Compared with nontargeted therapy, targeted therapies demonstrated a survival advantage for patients 65 years and older with metastatic renal cell carcinoma.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.